The Boston University Clinical and Translational Science Institute (BU CTSI) is an innovative CTSA clinical and translational research hub and catalyst for national CTSA network science. Boston University and partner, Boston Medical Center Health System (affiliate with Boston HealthNet, Boston Accountable Care Organization, VA Boston Health System, Edith Norse Rogers Veterans Hospital and the HealthCore/New England Research Institutes, Inc.) to comprise the members of the BU CTSI. We serve the largest URG and At Risk patient populations in New England. Our overarching theme is meant to emphasize our commitment to developing translational research infrastructure that is appropriate and innovative to meet the standards of the CTSA Network AND is uniquely designed to meet the needs and overcome the many barriers in partnering in research with patients at risk for poor health and outcomes. In order to address the health needs of these communities, the BU CTSI will support workforce development, collaboration across our stakeholders and integration of translational science across the lifespan of our Special Populations the through the development of a competent workforce, use of novel informatics, methods and processes that address disparities of health care. The BU CTSI Goals are:
Aim 1. Discover, demonstrate, deploy and disseminate novel methods in training that will enhance our entire translational science workforce and create opportunities for advancement.
Aim 2. Develop the most efficient, most representative clinical trials hub possible employing the integrated resources of all our partners.
Aim 3. Effect meaningful multi-directional relationships among all our community stakeholders that strengthen collaborative translational research across the lifespan of our special populations and enable novel approaches to integrating research into health care.
Aim 4. In collaboration with other CTSA hubs, discover, develop and disseminate innovative tools to improve research on treatments and diagnostics that address national health problems: The BU CTSI?s vision is to be the strongest possible advocate for, and participant in, translational research that serves the health needs of our diverse At Risk patient populations by working with our community to create unique resources that can be integrated with and distributed to the national CTSA network.

Public Health Relevance

Boston University, The Boston Medical Center Health System, Boston HealtNet, Boston Accountable Care Organization, VA Boston Health System, Edith Norse Rogers Veterans Hospital and the HealthCore/New England Research institutes, Inc comprise the members of the Boston University Clinical and Translational Science Institute (BU CTSI) Hub, supported by a Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Science of the NIH. The goals of the BU CTSI, funded since 2008, are: 1. to train a diverse workforce; 2. improve and expedite translational research across the members of the BU CTSI; 3. engage our community in research partnership; 4. develop new methods and resources that improve the science and performance of translational research.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
2UL1TR001430-05A1
Application #
10086522
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Talbot, Bernard
Project Start
2015-08-13
Project End
2025-03-31
Budget Start
2020-04-15
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Huiting, L N; Samaha, Y; Zhang, G L et al. (2018) UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response. Leukemia :
Meriin, Anatoli B; Narayanan, Arjun; Meng, Le et al. (2018) Hsp70-Bag3 complex is a hub for proteotoxicity-induced signaling that controls protein aggregation. Proc Natl Acad Sci U S A 115:E7043-E7052
Kim, Eun Ji; Kim, Taekyu; Conigliaro, Joseph et al. (2018) Racial and Ethnic Disparities in Diagnosis of Chronic Medical Conditions in the USA. J Gen Intern Med 33:1116-1123
Thomas, Dylan D; Istfan, Nawfal W; Bistrian, Bruce R et al. (2018) Protein sparing therapies in acute illness and obesity: a review of George Blackburn's contributions to nutrition science. Metabolism 79:83-96
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Stockman, Mary-Catherine; Thomas, Dylan; Burke, Jacquelyn et al. (2018) Intermittent Fasting: Is the Wait Worth the Weight? Curr Obes Rep 7:172-185
Brisimi, Theodora S; Chen, Ruidi; Mela, Theofanie et al. (2018) Federated learning of predictive models from federated Electronic Health Records. Int J Med Inform 112:59-67
Cooke, Margaret E; Hussein, Amira I; Lybrand, Kyle E et al. (2018) Correlation between RUST assessments of fracture healing to structural and biomechanical properties. J Orthop Res 36:945-953
Fricker, Zachary P; Pedley, Alison; Massaro, Joseph M et al. (2018) Liver Fat is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol :
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360

Showing the most recent 10 out of 83 publications